Any given human blood sample contains as many as 15,000 small biological molecules that can offer invaluable clues to the person’s health – yet fewer than 5% of these molecules can currently be identified. That’s where the Station R-based start-up Isospec Analytics hopes to make a difference – and save lives in the process.
Isospec, which is today announcing it has raised $1.9 million of pre-seed funding, operates in the field of biomolecular analysis technology. “Understanding disease mechanisms at the earliest possible stage is the most important work scientists can do to develop new treatments,” explains co-founder Ahmed Ben Faleh. “The small molecules in your blood are crucial if we want to do exactly that.”